EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily H Member 6-Like

Ensembl ID : ENSSTUG00000034724
Gene Symbol: LOC115169690
3 Cross references
150 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSSTUG00000039363
Gene Symbol: LOC115166075
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSSTUG00000030932
Gene Symbol: KCNQ2
3 Cross references
179 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSSTUG00000002400
Gene Symbol: KCNQ2
3 Cross references
180 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSSTUG00000029599
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSSTUG00000045011
Gene Symbol: KCNQ5
3 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSSTUG00000025248
Gene Symbol: KCNQ5
3 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSSTUG00000043540
Gene Symbol: KCNH2A
1 Cross references
151 Possible Orthologues:

Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 3-Like

Ensembl ID : ENSSTUG00000045251
Gene Symbol: LOC115196641
2 Cross references
209 Possible Orthologues:

Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 3-Like

Ensembl ID : ENSSTUG00000040180
Gene Symbol: LOC115167318
2 Cross references
215 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSSTUG00000017302
Gene Symbol: PSENEN
3 Cross references
172 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSSTUG00000037269
Gene Symbol: LOC115173027
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).